Fig. 2.

Effect of Ccr2 deficiency on glioma-bearing mice. (A) Survival analysis of KR158 tumor-bearing Ccr2^RFP/WT and Ccr2^RFP/RFP mice treated with or without anti-PD-1. Ccr2 deficiency did not impact survival in IgG-treated Ccr2^RFP/WT mice (n = 8), while anti-PD-1 treatment (n = 10) enhanced survival (P = 0.035) in Ccr2-deficient mice only. Triangles mark anti-PD-1 administration. (B) Fluorescent imaging of CD11b (green stain) in Ccr2^RFP/WT and Ccr2^RFP/RFP mice. Representative images shown. (C) Fluorescent imaging of femur cross-section from Ccr2^RFP/WT and Ccr2^RFP/RFP naive and KR158 tumor-bearing mice. Loss of Ccr2 enhanced CCR2/RFP signal in bone marrow of naive mice (P = 0.029), which was further enhanced in tumor-bearing Ccr2^RFP/RFP animals (P = 0.036). Representative images are shown. Quantification: average pixel density/cross-sectional area from 3 consecutive sections, 3 mice/treatment group. *P < 0.05.